Showing 1 posts of 1 posts found.
The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO